Pear Therapeutics, Inc. (PEAR): Price and Financial Metrics


Pear Therapeutics, Inc. (PEAR): $1.96

-0.04 (-2.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PEAR POWR Grades

  • PEAR scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.23% of US stocks.
  • The strongest trend for PEAR is in Growth, which has been heading down over the past 177 days.
  • PEAR ranks lowest in Growth; there it ranks in the 6th percentile.

PEAR Stock Summary

  • PEAR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.54 -- higher than only 4.96% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 23.89, PEAR THERAPEUTICS INC has a higher such ratio than 94.64% of stocks in our set.
  • Revenue growth over the past 12 months for PEAR THERAPEUTICS INC comes in at 172.08%, a number that bests 95.06% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to PEAR THERAPEUTICS INC, a group of peers worth examining would be DZSI, IBIO, SCWX, ALKS, and SQL.
  • To dig deeper into the stock's financial statements, go to PEAR's page on browse-edgar?action=getcompany&CIK=0001835567.

PEAR Valuation Summary

  • In comparison to the median Technology stock, PEAR's price/sales ratio is 838.46% higher, now standing at 24.4.
  • Over the past 22 months, PEAR's price/sales ratio has gone down 3.2.

Below are key valuation metrics over time for PEAR.

Stock Date P/S P/B P/E EV/EBIT
PEAR 2022-12-02 24.4 5.3 -9.2 -9.4
PEAR 2022-12-01 23.3 5.1 -8.8 -9.0
PEAR 2022-11-30 22.6 4.9 -8.5 -8.7
PEAR 2022-11-29 21.6 4.7 -8.1 -8.3
PEAR 2022-11-28 21.3 4.7 -8.0 -8.1
PEAR 2022-11-25 24.5 5.4 -9.2 -9.5

PEAR Stock Price Chart Interactive Chart >

Price chart for PEAR

PEAR Price/Volume Stats

Current price $1.96 52-week high $14.60
Prev. close $2.00 52-week low $1.34
Day low $1.95 Volume 149,700
Day high $2.09 Avg. volume 336,396
50-day MA $2.27 Dividend yield N/A
200-day MA $2.92 Market Cap 273.50M

Pear Therapeutics, Inc. (PEAR) Company Bio


Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.


PEAR Latest News Stream


Event/Time News Detail
Loading, please wait...

PEAR Latest Social Stream


Loading social stream, please wait...

View Full PEAR Social Stream

Latest PEAR News From Around the Web

Below are the latest news stories about PEAR THERAPEUTICS INC that investors may wish to consider to help them evaluate PEAR as an investment opportunity.

Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference

BOSTON, November 21, 2022--Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference

Yahoo | November 21, 2022

''The mood around here today is not great'': Pear Therapeutics trims workforce by another 22%

''The mood around here today is not great'': Pear Therapeutics trims workforce by another 22% apark Wed, 11/16/2022 - 09:50

FierceBiotech | November 16, 2022

Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR), Sutro Biopharma (STRO) and Pear Therapeutics (PEAR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Star Equity Holdings (STRR – Research Report), Sutro Biopharma (STRO – Research Report) and Pear Therapeutics (PEAR – Research Report) with bullish sentiments. Star Equity Holdings (STRR) Maxim Group analyst Tate Sullivan reiterated a Buy rating on Star Equity Holdings yesterday and set a price target of $2.25. The company's shares closed last Monday at $0.90, close to its 52-week low of $0.72. According to TipRanks.

Howard Kim on TipRanks | November 15, 2022

Pear Therapeutics undergoes another round of layoffs, cutting 22% of staff

The digital therapeutics company said the reductions will extend its cash runway and curb its reliance on financing.

BioPharma Dive | November 15, 2022

Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript

Pear Therapeutics Inc. (NASDAQ:NASDAQ:PEAR) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey…

Seeking Alpha | November 14, 2022

Read More 'PEAR' Stories Here

PEAR Price Returns

1-mo -24.32%
3-mo 2.62%
6-mo -28.47%
1-year -80.40%
3-year N/A
5-year N/A
YTD -68.39%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7412 seconds.